Dr. Amirah Aly is currently a Postdoctoral Fellow at the University of British Columbia where she is affiliated with the Centre for Molecular Medicine and Therapeutics, as well as the Department of Medical Genetics. She holds a PhD in Pharmacology from Northeastern University in Boston, where she established the efficacy of a novel intranasal GDNF gene therapy approach for treating Parkinson's disease. Amirah also holds a Bachelors of Pharmacy from Kuwait University.
Amirah's main research goals lie in overcoming the blood-brain barrier (BBB) to deliver disease-modifying therapeutics to the brain for treatment of neurodegenerative disorders. Her current postdoctoral research focuses on developing a non-invasive approach to deliver huntingtin-lowering antisense oligonucleotides to the brain for treatment of Huntington disease, using a novel nanoparticle platform that can penetrate the BBB.
For an up-to-date list of publications by Dr. Aly, please see ResearchGate.
University: University of British Columbia
Department: Medical Genetics
Position: Post-doctoral Fellow